P/E at 25.12 vs Industry's 33.21: What the Data Shows for Dr Reddys Laboratories Ltd

Valuation Picture: Discount Amidst Sector Premiums

The current P/E of 25.12 for Dr Reddys Laboratories Ltd stands in contrast to the industry average of 33.21, indicating a valuation discount of nearly one-quarter. This divergence suggests that the market is pricing in either a more cautious outlook on the company’s earnings growth or perceives higher risks relative to its peers. The sector’s elevated P/E reflects optimism around pharmaceutical innovation and growth prospects, yet Dr Reddys Laboratories Ltd appears to be trading on a more conservative multiple. Investors might wonder what is the current rating? given this valuation gap and the company’s recent performance.

Performance Across Timeframes: Mixed Momentum

Examining returns over various periods reveals a nuanced picture. Over the past year, Dr Reddys Laboratories Ltd delivered a modest gain of 0.32%, outperforming the Sensex’s decline of 8.46% during the same period. This relative resilience contrasts with the shorter-term trend, where the stock has underperformed. Over the last three months, the stock declined by 2.72%, while the Sensex fell by a steeper 6.28%. Year-to-date, the stock is down 1.18%, again outperforming the broader market’s 13.00% loss. However, the recent one-week and one-day performances show sharper declines of 4.78% and 0.52% respectively, compared to the Sensex’s 2.27% and 0.27% falls. This suggests that while the stock has demonstrated relative strength over longer horizons, short-term pressures have intensified — is this a recovery or a dead-cat bounce?

Moving Average Configuration: Bearish Technical Setup

The technical indicators for Dr Reddys Laboratories Ltd reveal a challenging trend. The stock is trading below all key moving averages — the 5-day, 20-day, 50-day, 100-day, and 200-day moving averages. This comprehensive positioning below short, medium, and long-term averages signals a sustained downtrend. The stock’s inability to breach these resistance levels suggests that recent rallies have not gained sufficient momentum to reverse the broader negative trend. The seven consecutive days of losses, amounting to a 5.49% decline, further reinforce the bearish technical picture. Such a configuration often indicates that the stock remains vulnerable to further downside pressure, raising the question should investors in Dr Reddys Laboratories Ltd hold, buy more, or reconsider?

Sector Performance Context: Mixed Results in Pharmaceuticals & Biotechnology

The Pharmaceuticals & Biotechnology sector has seen mixed results in recent earnings announcements. Out of 34 stocks that have declared results, 19 reported positive outcomes, 9 were flat, and 6 posted negative results. This distribution indicates a broadly stable sector environment with pockets of strength and weakness. Within this context, Dr Reddys Laboratories Ltd’s performance and valuation discount may reflect company-specific challenges or cautious investor sentiment despite the sector’s overall resilience. The sector’s average P/E of 33.21 underscores the premium investors are willing to pay for growth and innovation, which contrasts with the more conservative valuation of Dr Reddys Laboratories Ltd.

Rating Reassessment: From Buy to Hold

Previously rated Buy by MarketsMOJO, Dr Reddys Laboratories Ltd had its rating updated on 04 May 2026. The Mojo Score currently stands at 51.0, reflecting a Hold stance. This shift in rating aligns with the valuation discount and the technical weakness observed. The reassessment appears to factor in the stock’s recent underperformance relative to its historical trends and sector peers. The rating update invites investors to consider what is the current rating? in light of the evolving data landscape.

Long-Term Performance: Outperformance Over Several Years

Looking beyond the recent volatility, Dr Reddys Laboratories Ltd has delivered strong returns over longer horizons. The three-year return stands at 36.26%, nearly doubling the Sensex’s 18.54% gain over the same period. However, the five-year return of 19.55% trails the Sensex’s 42.31%, and the ten-year return of 98.78% is below the Sensex’s 176.21%. This mixed long-term performance suggests that while the company has had periods of significant outperformance, it has not consistently kept pace with the broader market over the past decade. The current valuation discount may partly reflect this uneven track record.

Intraday and Recent Price Action

On 04 June 2026, Dr Reddys Laboratories Ltd opened at ₹1,258.95 and traded inline with its sector, closing with a slight decline of 0.52%. The stock’s recent seven-day losing streak, with a cumulative fall of 5.49%, highlights the short-term selling pressure. This contrasts with the sector’s more moderate declines, suggesting company-specific factors may be influencing investor sentiment. The persistent weakness below all major moving averages reinforces the cautious technical outlook.

Conclusion: A Complex Data Narrative

The data on Dr Reddys Laboratories Ltd paints a multifaceted picture. The stock trades at a meaningful discount to its sector’s P/E, reflecting tempered expectations or risk considerations. While it has outperformed the Sensex over the past year and three months, recent weeks have seen sharper declines and a bearish technical setup. The sector’s mixed earnings results and the company’s rating reassessment from Buy to Hold further underscore the cautious stance. Taken together, these factors invite investors to carefully analyse should investors in Dr Reddys Laboratories Ltd hold, buy more, or reconsider?

Get 33% Off on our 1 Year Plan - Limited Period Only! Start Today